Plexxikon - Oncology


	While all cancers display uninterrupted cell proliferation, their heterogeneity often makes them difficult to treat. Given these characteristics, Plexxikon is pursuing a number of drug targets for the treatment of different cancers. Melanoma and Colorectal Cancer PLX4032 is Plexxikon's lead program in its oncology developing franchise, now in a Phase 1 clinical trial. This drug candidate selectively targets the B-Raf^V600E gene, a mutation that has been shown to drive certain cancers. This pivotal mutation occurs only in tumor cells and affects approximately 70% of malignant melanomas, as well as a large number of colorectal and thyroid cancers. Since September 2006, Plexxikon has been co-developing PLX4032 with Roche. Additionally, the two companies are co-developing a diagnostic test to select patients who carry the B-Raf^V600E mutation and would be likely responders to this agent. Osteolytic Metastatic Disease Plexxikon has developed a portfolio of novel drug candidates designed to treat diseases primarily driven by osteoclasts and macrophages — both cells of the immune system. These cell types drive certain cancers and inflammatory diseases. The company is developing a candidate for the treatment of osteolytic metastatic disease in breast cancer and multiple myeloma. Oncology: Melanoma and Colorectal Cancer Program Fact Sheet Oncology: Osteolytic Metastatic Disease Program Fact Sheet

| | | | |

| | | | | | |